Riskpilot← Back to searchSign inGet full accessDaimon Medicine AB
ABActiveOrg 5592925639Fendergatan 13Medical specialists activities · NACE 8622Est. 20200 employees
Revenue 2024
SEK 0
EBITDA margin
—
-123% vs 2023
Equity ratio
82.0%
Financial strength
Net profit 2024
SEK -37K
-254% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -9K | -123% |
| Net profit | SEK -37K | -254% |
| Total assets | SEK 100K | -29% |
| Equity | SEK 82K | -31% |
| Employees | 0 | — |
Legal name
Daimon Medicine AB
Org number
5592925639
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
21 december 2020
Share capital
SEK 25 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska: 1) Bedriva medicinsk konsultverksamhet och sjukvård utförd av legitimerad läkare. 2) Utveckling av hjälpmedel och material för användning vid interventioner via kärlsystemet och vid operationer.
Address
Fendergatan 13
Email
bo.sahlgren@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 38 | 74 | 50 | 0 |
| Staff expenses | — | — | — | — |
| EBITDA | 24 | 64 | 40 | −9 |
| Depreciation & amort. | −0 | −0 | −0 | −0 |
| EBIT | 24 | 64 | 40 | −9 |
| Net financials | — | −1 | −2 | −2 |
| Profit before tax | 24 | 63 | 39 | −11 |
| Tax | −5 | −5 | −15 | −26 |
| Net profit | 19 | 58 | 24 | −37 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 46 | 107 | 141 | 100 |
| Equity | 44 | 94 | 118 | 82 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 2 | 13 | 23 | 18 |
| Total debt | 2 | 13 | 23 | 18 |
EBITDA margin
-900000.0%
This company
15.8%
Market median
-5696303% vs market
20212024
Equity ratio
82.0%
This company
38.2%
Market median
+115% vs market
20212024
Return on equity
-45.1%
This company
18.4%
Market median
-345% vs market
20212024
Net profit margin
-3700000.0%
This company
8.1%
Market median
-45679112% vs market
20212024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212024
Debt / equity
0.22×
This company
0.62×
Market median
+65% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-12-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Daimon Medicine AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Åke Sahlgren | Board of Directors | 0 companies |
| Anna May Heller | Deputy Board Member | 0 companies |